Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3Lung Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Metastatic Pancreatic Adenocarcinoma 1Lymphoma, T-Cell 1Leukemia, Myeloid, Acute 1Central Nervous System Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Leucovorin 3Gemcitabine 3Fluorouracil 3pembrolizumab 2irinotecan sucrosofate 2Irinotecan 2Albumin-Bound Paclitaxel 24-fluorobenzoyl-TN-14003 2olaparib 1ibrutinib 1adavosertib 1Tetrahydrouridine 1Paclitaxel 1PEGPH20 1Oxaliplatin 1Drug Therapy 1Docetaxel 1Decitabine 1Cisplatin 1Capecitabine 1BKT140 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Pancreatic Adenocarcinoma × Tetrahydrouridine × Clear all
NCT02847000 2019-01-09

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
13 enrolled
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡